Reuters reveals Novavax executives could get big payday even if vaccine fails | Reuters News Agency
Business & FinanceHealth

Reuters reveals Novavax executives could get big payday even if vaccine fails

Reuters exclusively reported that one of the leading U.S. firms developing a coronavirus vaccine, Novavax Inc, has awarded executives stock options that could pay out tens of millions of dollars even if its efforts fail. The incentive plan, which has not been previously reported, allows the executives to start exercising the options a year after Novavax starts the so-called Phase 2 trial, as it expects to do soon. The Maryland-based company has not brought a vaccine to market in its 33-year history. But its market value has rocketed from $250 million to $8 billion in about five months on news of its coronavirus vaccine prospects.

Article Tags
Topics of Interest: Business & FinanceHealth
Type: Reuters Best
Sectors: Equities
Regions: North America
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
FILE PHOTO: Dr Francis Collins, director of the National Institutes of Health (NIH), holds up a model of SARS-CoV-2, known as the novel coronavirus,  during a U.S. Senate Appropriations Subcommittee Hearing on the plan to research, manufacture and distribute a coronavirus vaccine, known as Operation Warp Speed on Capitol Hill in Washington, D.C, U.S., July 2, 2020. Saul Loeb/Pool via REUTERS/File Photo - RC2BYH9UYBY3
Sign up for email updates
Subscribe
Sign up for email updates